Table 2.

Dosage and administration requirements for glucagon-like peptide-1 receptor agonists based on European Union summary of product characteristics of each agent

Drug	Titration	Initial dosage	Recommended dosage	Administration in relation to meals	Missed dose
Once-daily
Exenatide	Yes	5 mcg BID for at least 1 month	5–10 mcg BIDb	Should be administered within 60 min before main meals	Continue with the next scheduled dose
Liraglutide	Yes	0.6 mg OD for at least 1 week	1.2–1.8 mg ODc	At any time, without regard to meals	≤ 12 h: administer the dose as soon as possible > 12 h: skip the dose
Lixisenatide	Yes	10 mcg OD for 14 days	20 mcg OD	Should be administered within 60 min before any meal	Administer the dose within 1 h before the next meal
Once-weekly
Exenatide	No	Not applicable	2 mg once weekly	At any time, without regard to meals	Administer the next dose as soon as practical. Only one injection should be administered in a 24-h period
Dulaglutide	Noa	Not applicable	Monotherapy: 0.75 mg once weekly Add-on therapy: 1.5 mg once weekly	At any time, without regard to meals	≥ 3 days until the next scheduled dose: administer the dose as soon as possible < 3 days: skip the dose, wait and administer their next regularly scheduled weekly dose
Semaglutide	Yes	0.25 mg once weekly for 4 weeks	0.5–1.0 mg once weekly (dose increase after 4 weeks if required)	At any time, without regard to meals	≥ 5 days until the next scheduled dose: administer the dose as soon as possible < 5 days: skip the dose, wait and administer their next regularly scheduled weekly dose

Data were extracted from references [15–20, 30]

BID Twice a day, OD once daily

^aIn elderly patients, a lower dose of 0.75 mg once weekly can be considered

^bImmediate-release exenatide should be initiated at 5 mcg per dose administered BID for at least 1 month to improve tolerability; the dose can then be increased to 10 mcg BID to further improve glycemic control

^cLiraglutide should be initiated at a dose of 0.6 mg daily to improve gastrointestinal tolerability; after at least 1 week, the dose should be increased to 1.2 mg and a further increase to 1.8 mg may be required to further improve glycemic control